Company Q&A | CanSino: Currently advancing the research and development of mRNA vaccines for the treatment of glioblastoma, rhabdomyosarcoma, and other indications.

Gelonghui, May 14 | An investor asked CanSino on an interactive platform: "Has there been any progress on the cancer‑therapeutic vaccine mentioned in your previous announcement?" CanSino replied that, while continuing to strengthen its core business, the company is exploring product opportunities in the therapeutic space. It is currently advancing R&D on mRNA vaccines for indications such as glioblastoma and rhabdomyosarcoma, and will continue to build out its pipeline of candidate products. The company will also seize potential collaboration opportunities and explore various possibilities, taking into account the distinct characteristics of each product, the competitive landscape, and its future value prospects.

Gelonghui FinanceMay 14 15:34

Abnormal Fluctuation Statistics of Shanghai-Hong Kong Stock Connect | May 14

Intelligent Channel HK Stock Connect Ratio Anomaly Statistics | May 13, 2026

Zhitong FinanceMay 14 08:36

H-share Announcements | China Jinmao achieved a cumulative contracted sales amount of 31.234 billion yuan in the first four months, representing a year-on-year increase of 23.44%.

Tuya Inc reported a net profit of US$15.8 million in the first quarter, representing a year-on-year increase of 43.2%. Revenue from its AI business grew by 16.9%, emerging as a new growth driver. China Jinmao achieved cumulative contracted sales of RMB31.234 billion in the first four months, marking a year-on-year increase of 23.44%.

Zhitong FinanceMay 12 09:05

CanSino Biologics (06185.HK): The NDA for the Td5cp vaccine for adolescents and adults has been granted priority review by the Center for Drug Evaluation of the National Medical Products Administration.

CanSino Biologics (06185.HK) announced that the New Drug Application (NDA) for its adsorbed acellular pertussis (five-component) diphtheria and tetanus combined vaccine (for use in individuals aged 6 years and above) ("Td5cp for adolescents and adults") has been granted priority review status by the Center for Drug Evaluation of the China National Medical Products Administration. According to the regulations governing priority review and approval, the Center will allocate resources preferentially to evaluate NDAs included in this process. Td5cp for adolescents and adults is suitable for individuals aged 6 years and above and serves as a booster vaccine against diphtheria, tetanus, and pertussis for adolescents and adults.

Gelonghui FinanceMay 11 16:48

Express News | 14:00 Quick Commentary: Significant divergence between the Huangbai lines, with localized strength in short-term sentiment.

BreakingsMay 11 14:07

A-share market movement | The Hantavirus outbreak draws attention! The virus prevention and treatment sector collectively surged, with Wantai Biotech up 9% and BGI Genomics rising over 5%.

Gelonghui, May 11 | Virus prevention and control concept stocks collectively rose in the A-share market. Among them, Walvax Biotech surged 19%, Capricorn Bio-Tech increased by over 15%, Daan Gene hit a 10% price limit, Wantai BioPharm gained 9%, Kangtai Biological Products rose over 8%, Zhifei Biological Products climbed 7%, and Frontier Biopharma-U, Probiotics Pharmaceuticals, CanSino Biologics, Wondfo Biotech, and Kanghua Biological Products increased by over 6%. Additionally, Jindike Biologics, BGI Group, Sichuan Maik Biotechnology, and TopRim Pharmaceuticals saw gains exceeding 5%. In terms of news, the cruise ship 'Hondeus' recently reported an outbreak of Hantavirus. Furthermore, a fatal case of Hantavirus was reported in Taipei City, Taiwan, related to infections carried by rats, drawing significant public attention.

Gelonghui FinanceMay 11 13:35